Is Testosterone Replacement Therapy Safe Long-Term?

Testosterone replacement therapy is broadly considered safe for long-term use in men who have clinically diagnosed hypogonadism, meaning genuinely low testosterone confirmed by blood tests and accompanied by symptoms. In this context, current evidence supports meaningful benefits with manageable risks under medical supervision. That said, long-term safety is not unconditional — it depends heavily on why testosterone is being used, how it is monitored, and the individual’s underlying health profile.

What Is Testosterone Replacement Therapy?

TRT is a medical treatment designed to restore testosterone to physiologically normal levels in men whose levels have fallen below the clinical threshold. It is prescribed for hypogonadism, which can result from ageing, testicular dysfunction, pituitary problems, or other conditions. Common delivery methods include injections, gels, patches, and pellets.

Testosterone plays a central role in muscle mass, bone density, red blood cell production, libido, mood, and metabolic function. When levels decline significantly, these areas can deteriorate in ways that affect quality of life. TRT aims to restore those functions — not to push testosterone above the physiological range.

It is worth distinguishing TRT from testosterone use in men with normal levels seeking performance or anti-ageing benefits. These are meaningfully different scenarios with different risk profiles, and the evidence base does not apply equally to both.

Long-Term Safety: What the Evidence Shows

The evidence on long-term TRT safety has improved substantially over the past decade. The TRAVERSE trial, published in 2023, was a large randomised controlled trial specifically designed to assess cardiovascular safety in middle-aged and older men with hypogonadism and pre-existing cardiovascular risk. It found no significant increase in major adverse cardiovascular events compared to placebo over a median follow-up of around 33 months — a notable finding that helped clarify earlier uncertainty.

However, the trial did identify a higher incidence of certain adverse events in the TRT group, including pulmonary embolism, atrial fibrillation, and acute kidney injury. These findings reinforce that TRT is not without risk, and that patient selection and monitoring remain critical.

Overall, current evidence supports that TRT is reasonably safe for appropriately selected men with true hypogonadism under medical supervision. Long-term data beyond several years remain limited, and the evidence is substantially weaker for men without confirmed deficiency.

For a broader view of how testosterone therapy fits within the landscape of drug-based longevity interventions, see our overview of longevity drugs: what is promising and what is premature.

Cardiovascular Risk and TRT

Cardiovascular safety has historically been the primary concern with long-term TRT. Earlier observational studies raised alarms, though many were methodologically limited. The TRAVERSE trial provided more robust data and was reassuring in terms of major cardiac events, but it also raised new concerns about thromboembolic events and arrhythmias that require attention.

One consistent finding across studies is that TRT raises haematocrit — the proportion of red blood cells in the blood. Elevated haematocrit increases blood viscosity and, as a result, raises the risk of clotting complications including deep vein thrombosis and pulmonary embolism. This is one reason regular blood monitoring is considered non-negotiable during TRT.

TRT can also affect lipid profiles, though effects are variable depending on the formulation used. Injectable testosterone tends to suppress HDL cholesterol more than transdermal preparations. In practice, this means cardiovascular risk markers should be assessed at baseline and monitored throughout treatment.

Men with pre-existing cardiovascular disease, a history of thromboembolic events, or poorly controlled risk factors require especially careful evaluation before starting TRT.

Prostate Health and TRT

Concerns about TRT and prostate cancer have historically been prominent, rooted in the fact that prostate cancer cells are sensitive to androgens. For decades, the assumption was that raising testosterone would fuel cancer growth. However, current evidence does not support a straightforward causal link between TRT and the development of prostate cancer in men without pre-existing disease.

The “saturation model” — developed by Abraham Morgentaler and others — proposes that prostate tissue becomes saturated with androgens at relatively low testosterone levels, meaning that restoring testosterone to the normal range does not meaningfully increase prostate stimulation beyond what already exists. This model is now broadly accepted in the field, though it remains an area of ongoing research.

That said, TRT is contraindicated in men with existing or suspected prostate cancer, and PSA monitoring remains a standard part of long-term TRT management. Benign prostatic hyperplasia (BPH) may also be worsened by TRT in some men, and urinary symptoms should be assessed before and during treatment.

TRT for Deficiency vs. Enhancement in Healthy Men

A critical distinction in the TRT safety debate is whether a man has genuine hypogonadism or simply has testosterone levels in the lower portion of the normal range without clear clinical symptoms.

For men with confirmed deficiency, the evidence-to-risk ratio is reasonably favourable. In contrast, using TRT in men with normal or low-normal testosterone — whether for energy, body composition, or anti-ageing purposes — is a different clinical scenario with a less clearly favourable risk-benefit balance. This use is increasingly common but lacks robust long-term safety data in that specific population.

From a longevity perspective, this matters considerably. Restoring a deficient hormone to a physiological range is not the same as adding a hormone to a system that does not require it. The latter approach carries more uncertainty and cannot be considered low-risk simply because the hormone is endogenous.

This distinction — between correcting deficiency and using hormones for enhancement — applies equally to other hormone interventions discussed in this cluster. For more context, see our article on whether growth hormone extends lifespan, which illustrates why hormone enhancement in healthy people can conflict with longevity pathways even when short-term markers improve.

Monitoring and Medical Oversight

Long-term TRT safety depends substantially on the quality of medical oversight. The Endocrine Society and other professional bodies recommend a structured monitoring protocol that typically includes:

• Baseline assessment of testosterone levels, PSA, full blood count, lipid profile, and cardiovascular risk factors
• Follow-up blood tests at 3–6 months after initiation, then annually if stable
• Haematocrit monitoring to manage polycythaemia risk
• PSA and digital rectal examination for prostate surveillance
• Assessment of symptom response and any emerging side effects

Dose adjustments should target mid-normal physiological testosterone levels, not supraphysiological ranges. Staying within the normal reference range reduces risk substantially compared to aggressive dosing. TRT should not be initiated or managed without specialist involvement, particularly where cardiovascular risk factors or prostate concerns are present.

Lifestyle, Foundations, and TRT

TRT does not replace the foundations of healthy ageing. Resistance training, adequate sleep, a nutrient-dense diet, and stress management all support testosterone levels naturally and reduce the downstream effects of age-related decline. In some men, addressing lifestyle factors reduces symptoms of low testosterone without requiring pharmacological intervention.

For those who do require TRT, lifestyle foundations remain important. Exercise — particularly resistance training — amplifies many of the benefits associated with testosterone, including muscle mass preservation and metabolic function. Obesity also suppresses testosterone and increases oestrogen conversion, so weight management is directly relevant to both baseline levels and treatment outcomes.

In the wider longevity context, the evidence continues to support lifestyle interventions as the most established and lowest-risk foundation for healthspan extension. Drug-based interventions, including TRT, may add value in specific circumstances but are not substitutes for these fundamentals. Learn more in our complete guide to longevity at longevityinsights.co.uk/what-is-longevity/.

References

Conclusion

Testosterone replacement therapy can be safe long-term for men with clinically confirmed hypogonadism, provided it is managed with appropriate medical oversight, regular monitoring, and realistic expectations. However, the evidence does not straightforwardly support TRT as a longevity or anti-ageing intervention for men with normal testosterone levels. The distinction between correcting a genuine deficiency and using hormones for enhancement is clinically significant — and risk profiles differ accordingly. As with all drug-based approaches to healthy ageing, the foundations of lifestyle, sleep, exercise, and nutrition remain the most established tools, with pharmacological interventions reserved for specific, well-defined clinical contexts.